2-((2-aminoethylamino)carbonylethylphenylethylamino)-5'-n-ethylcarboxamidoadenosine profile

The chemical name you provided, **2-((2-aminoethylamino)carbonylethylphenylethylamino)-5'-n-ethylcarboxamidoadenosine**, is a complex molecule with a very specific structure. It's not a commonly known compound, and there is no readily available information on its specific applications or significance in research.

However, based on its structure, it seems likely to be a synthetic compound with potential as a:

* **Ligand or inhibitor:** The complex structure, with its amino groups and aromatic rings, could potentially bind to specific protein receptors or enzymes. This could make it useful as a ligand for studying receptor function or as an inhibitor for blocking specific enzymatic pathways.
* **Bioactive molecule:** The presence of adenosine, a molecule known for its biological activity, suggests that this compound might have its own unique effects on cellular processes.

To understand the importance of this compound for research, we would need more context:

* **Who synthesized it?** The researchers or laboratory that developed this compound might have specific research interests.
* **What was the purpose of its synthesis?** The researchers may have designed it to target a specific protein or cellular pathway.
* **What are the observed biological effects?** If the compound has been tested, its biological effects would reveal its potential applications.

**In summary:**

Without further information, it's impossible to definitively say why this specific compound is important for research. However, its complex structure suggests potential applications as a ligand, inhibitor, or bioactive molecule. Further research is needed to determine its specific significance.

2-((2-aminoethylamino)carbonylethylphenylethylamino)-5'-N-ethylcarboxamidoadenosine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	3081741
CHEMBL ID	1950647
SCHEMBL ID	8095238
MeSH ID	M0174590

Synonym
126828-50-0
2-((2-aminoethylamino)carbonylethylphenylethylamino)-5'-n-ethylcarboxamidoadenosine
beta-d-ribofuranuronamide, 1-(6-amino-2-((2-(4-(3-((2-aminoethyl)amino)-3-oxopropyl)phenyl)ethyl)amino)-9h-purin-9-yl)-1-deoxy-n-ethyl-
apec-2
(2s,3s,4r,5r)-5-[6-amino-2-[2-[4-[3-(2-aminoethylamino)-3-oxopropyl]phenyl]ethylamino]purin-9-yl]-n-ethyl-3,4-dihydroxyoxolane-2-carboxamide
bdbm50364060
CHEMBL1950647 ,
SCHEMBL8095238
DTXSID40155301
2-((2-aminoethylamino)carbonylethylphenylethylamino)-5/'-n-ethylcarboxamidoadenosine

Excerpt	Relevance	Reference
" An A1-selective, centrally acting, adenosine antagonist, 8-cyclopentyltheophylline (10 mg/kg), completely reversed the locomotor depressant effects of CHA (A1-selective) and NECA (nonselective) at doses of agonists as high as twice the ED50, and shifted the dose-response curves to the right, suggesting a primary involvement of A1 receptors."	( Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. Daly, JW; Jacobson, KA; Nikodijević, O; Sarges, R, 1991)	0.28
" From dose-response curves it was found that APEC (ED50 16 micrograms/kg) is more potent than CHA (ED50 60 micrograms/kg) and less potent than NECA (ED50 2 micrograms/kg)."	( Characterization of the locomotor depression produced by an A2-selective adenosine agonist. Daly, JW; Jacobson, KA; Nikodijević, O, 1990)	0.28

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Adenosine receptor A1	Rattus norvegicus (Norway rat)	Ki	0.2400	0.0001	1.2092	9.9700	AID32177
Adenosine receptor A3	Rattus norvegicus (Norway rat)	Ki	0.0500	0.0003	0.9196	9.0000	AID33485
Adenosine receptor A2b	Rattus norvegicus (Norway rat)	Ki	0.0057	0.0006	1.3536	10.0000	AID33584
Adenosine receptor A2a	Rattus norvegicus (Norway rat)	Ki	0.0057	0.0002	1.4940	10.0000	AID33584; AID33939; AID647890
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
G protein-coupled adenosine receptor activity	Adenosine receptor A2a	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
Golgi membrane	Adenosine receptor A2a	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID33752	Ratio of A2 to A1.	1992	Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3	Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID33939	Tested for the binding affinity of A2a receptor by displacing the [3H]-CGS- 21680 in rat striatal membranes	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.
AID1138055	Induction of hypolocomotion in po dosed rat assessed as reduction in motor deficts	2014	Journal of medicinal chemistry, May-08, Volume: 57, Issue:9	Adenosine A2A receptor as a drug discovery target.
AID32513	Tested for the binding affinity of A1 receptor by displacing the [3H]-PIA in rat brain membranes	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.
AID229821	Ratio of Ki for A1 and A3 receptors	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.
AID647890	Displacement of [3H]NECA from A2A adenosine receptor expressed in rat striatal membranes after 30 mins by liquid scintillation counting	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.
AID33584	Binding affinity for adenosine A2 receptor using [3H]- NECA	1992	Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3	Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID33485	Tested for the binding affinity of A3 receptor by displacing N6-[[125I]-4-amino-3-iodobenzyl]-adenosine-5''-N-methyluronamide from membranes of CHO cells transfected with rat A3-cDNA	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.
AID230000	Ratio of Ki for A2a and A3 receptors	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.
AID32177	Binding affinity against adenosine A1 receptor using [3H]-CHA or [3H]PIA as radioligand	1992	Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3	Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	10 (71.43)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (21.43)	24.3611
2020's	1 (7.14)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (14.29%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	12 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
1,3-dipropyl-8-cyclopentylxanthine DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group.	3.48	2	oxopurine	adenosine A1 receptor antagonist; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.	1.99	1	methylpyridines; phenylpyridine; tetrahydropyridine	neurotoxin
8-(4-sulfophenyl)theophylline 8-(4-sulfophenyl)theophylline: adenosine antagonist	3.48	2
8-cyclopentyl-1,3-dimethylxanthine 8-cyclopentyl-1,3-dimethylxanthine: prolongs epileptic seizures in rats	3.48	2	oxopurine
8-phenyltheophylline 8-phenyltheophylline: purinergic P1 receptor antagonist	3.08	1
theophylline [no description available]	4.85	6	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
caffeine [no description available]	4.53	4	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
cgs 15943 9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine: non-xanthine triazoloquinazoline adenosine antagonist. CGS 15943 : A member of the class of triazoloquinazolines that is [1,2,4]triazolo[1,5-c]quinazoline substited at positions 2, 5 and 9 by furan-2-yl, amino and chloro groups respectively. A potent antagonist at adenosine A1 and adenosine A2A receptors.	4.03	2	aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline	adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant
theobromine Theobromine: 3,7-Dimethylxanthine. The principle alkaloid in Theobroma cacao (the cacao bean) and other plants. A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than THEOPHYLLINE and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9). theobromine : A dimethylxanthine having the two methyl groups located at positions 3 and 7. A purine alkaloid derived from the cacao plant, it is found in chocolate, as well as in a number of other foods, and is a vasodilator, diuretic and heart stimulator.	2	1	dimethylxanthine	adenosine receptor antagonist; bronchodilator agent; food component; human blood serum metabolite; mouse metabolite; plant metabolite; vasodilator agent
8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine 8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine: adenosine receptor antagonist	3.08	1
2-chloroadenosine 5-chloroformycin A: structure given in first source	4.3	3	purine nucleoside
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	4.89	11	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
rolofylline rolofylline: selective antagonist for adenosine receptors; a cardiovascular agent	3.08	1	oxopurine
n(6)-benzyladenosine N(6)-benzyladenosine: RN given refers to parent cpd	1.98	1
1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine [no description available]	3.08	1
phenylisopropyladenosine [no description available]	3.08	1	aromatic amine; benzenes; hydrocarbyladenosine; purine nucleoside; secondary amino compound	adenosine A1 receptor agonist; neuroprotective agent
3,7-dimethyl-1-propargylxanthine 3,7-dimethyl-1-propargylxanthine: potent & selective in vivo antagonist of adenosine analogs	3.49	2
n(6)-phenyladenosine [no description available]	3.08	1	purine nucleoside
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist. 3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group.	2.39	2	adenosines; monocarboxylic acid amide; organoiodine compound	adenosine A3 receptor agonist
2-chloro-n(6)cyclopentyladenosine 2-chloro-N(6)cyclopentyladenosine: highly selective agonist at A1 adenosine receptors	3.48	2
cp 66713 CP 66713: adenosine receptor antagonist; structure given in first source	3.08	1
adenosine amine congener adenosine amine congener: a highly potent & selective adenosine A1 receptor agonist	3.08	1
8-(4-carboxymethyloxy)phenyl-1,3-dipropylxanthine 8-(4-carboxymethyloxy)phenyl-1,3-dipropylxanthine: used to localize adenosine receptors in the brain	3.08	1
8-(dicyclopropylmethyl)-1,3-dipropylxanthine 8-(dicyclopropylmethyl)-1,3-dipropylxanthine: selective A1 adenosine receptor antagonist; structure given in first source	3.08	1
kfm 19 KFM 19: a potential cognitive enhancer and a selective adenosine A1 receptor antagonist	3.08	1
2-(1-octynyl)adenosine YT 146: an adenosine receptor agonist; structure given in first source	3.08	1
zm 241385 ZM 241385: a high affinity radioligand selective for the A2a adenosine receptor	3.19	1	diamino-1,3,5-triazine
sch 58261 [no description available]	3.19	1	triazolopyrimidines
regadenoson [no description available]	3.59	2	purine nucleoside
8-cyclohexylcaffeine [no description available]	3.08	1
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	2	1	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
adenosine-5'-(n-ethylcarboxamide) Adenosine-5'-(N-ethylcarboxamide): A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.. N-ethyl-5'-carboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group.	4.86	6	adenosines; monocarboxylic acid amide	adenosine A1 receptor agonist; adenosine A2A receptor agonist; antineoplastic agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
wr-142,490 (+)-(11R,2'S)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (+)-(11R,2'S)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.	3.19	1	[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol	antimalarial
n(6)-cyclopentyladenosine [no description available]	3.48	2
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: structure given in first source	1.98	1
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine: A2 adenosine receptor agonist; structure given in first source. CGS-21680 : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and the hydrogen at position 2 on the adenine is replaced by a 4-(2-carboxyethyl)phenethylamino group.	4.72	5	adenosines; dicarboxylic acid monoamide; monocarboxylic acid	adenosine A2A receptor agonist; anti-inflammatory agent
istradefylline [no description available]	3.53	2	oxopurine
8-(3-chlorostyryl)caffeine 8-(3-chlorostyryl)caffeine: adenosine antagonist. 8-(3-chlorostyryl)caffeine : Caffeine substituted at its 8-position by an (E)-3-chlorostyryl group.	2.4	2	monochlorobenzenes; trimethylxanthine	adenosine A2A receptor antagonist; EC 1.4.3.4 (monoamine oxidase) inhibitor
cv 1808 2-phenylaminoadenosine: has coronary & cardiohemodynamic effects	4.03	2	purine nucleoside
binodenoson [no description available]	3.59	2
atl 146e BMS-068645: structure in first source	3.59	2
uk-432097 UK-432097: a highly potent and selective agonist and drug candidate for chronic obstructive pulmonary disease (COPD) treatment; structure in first source	2.07	1
n(6)-cyclohexyladenosine N(6)-cyclohexyladenosine: structure given in first source; receptors, purinergic P1 agonist	3.48	2
st 1535 [no description available]	3.19	1
2-(2-(4-chlorophenyl)ethoxy)adenosine 2-(2-(4-chlorophenyl)ethoxy)adenosine: a adenosine A2A receptor agonist	3.59	2
3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine 3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodo-4-aminobenzyl group.	1.98	1	adenosines; monocarboxylic acid amide; organoiodine compound
2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7h-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine [no description available]	3.19	1
n(6)-(2,2-diphenylethyl)adenosine N(6)-(2,2-diphenylethyl)adenosine: adenosine receptor agonist; structure given in first source	3.51	2
cgs 24012 CGS 24012: adenosine agonist with both high affinity & selectivity for the adenosine A2 receptor	3.08	1
tozadenant tozadenant: an adenosine A2A receptor antagonist	3.19	1	benzothiazoles
atl 313 ATL 313: A2A adenosine receptor agonist	2.07	1
v 2006 3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine: antiparkinson agent; structure in first source	3.19	1

Condition	Relationship Strength	Studies
Biliary Calculi [description not available]	2.6	1
Acute Edematous Pancreatitis [description not available]	2.6	1
Acute Disease Disease having a short and relatively severe course.	2.6	1
Cholangitis Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.	2.6	1
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	2.6	1
Gallstones Solid crystalline precipitates in the BILIARY TRACT, usually formed in the GALLBLADDER, resulting in the condition of CHOLELITHIASIS. Gallstones, derived from the BILE, consist mainly of calcium, cholesterol, or bilirubin.	2.6	1
E coli Infections [description not available]	2.21	1
Poultry Diseases Diseases of birds which are raised as a source of meat or eggs for human consumption and are usually found in barnyards, hatcheries, etc. The concept is differentiated from BIRD DISEASES which is for diseases of birds not considered poultry and usually found in zoos, parks, and the wild.	2.21	1
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	2.21	1
Cerebral Ischemia [description not available]	1.98	1
Brain Vascular Disorders [description not available]	1.98	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	1.98	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	1.98	1
Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.	1.98	1
Atherosclerotic Parkinsonism [description not available]	1.99	1
Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)	1.99	1
Drug Withdrawal Symptoms [description not available]	2	1
Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.	2	1
Allodynia [description not available]	1.98	1

2-((2-aminoethylamino)carbonylethylphenylethylamino)-5'-n-ethylcarboxamidoadenosine

Description

Cross-References

Synonyms (10)

Research Excerpts

Dosage Studied

Protein Targets (4)

Inhibition Measurements

Molecular Functions (1)

Ceullar Components (1)

Bioassays (10)

Research

Studies (14)

Market Indicators

Research Demand Index: 11.74

Study Types